Personalized medicine is an exciting space that is moving and changing quickly. Staying on top of the changes and identifying parallel opportunities is difficult. How do you identify what disease areas are complementary to your existing product strategy? What is...
In mid-2015 we worked hard to add a new source of evidence for biomarkers: Laboratory Developed Tests, or LDTs. This was a huge milestone for Amplion. We successfully used our technology to identify biomarkers in a new information source very quickly without...
In a follow on to our trial filtering changes we made in February, this week we have added a couple more options to trial filtering: Filtering biomarkers to those used as outcome and safety measures Filtering trials to only those with results Insights view of...
Anyone involved in biomarkers knows how imperative it is to stay informed about biomarker developments. Here at Amplion, we aggregate and annotate cutting edge biomarker information and publish it in BiomarkerBase, so you can stay up to date on the clinical biomarker...
We have just completed the latest data update to BiomarkerBase, which includes the following new information: 1,161 Biomarkers (unique Target/Disease combinations) 3 Diseases 5 Drugs As we mentioned in our last product update post, this is the second of a few product...
